{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T03:37:32Z","timestamp":1774669052022,"version":"3.50.1"},"reference-count":79,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.det.2024.12.016","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T12:52:07Z","timestamp":1737463927000},"page":"359-371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Future Directions and Pipeline Therapies for Hidradenitis Suppurativa"],"prefix":"10.1016","volume":"43","author":[{"given":"Kim T.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniella","family":"Jaguan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah","family":"Goldfarb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.det.2024.12.016_bib1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00403-024-03121-x","article-title":"The use of biologics and JAK inhibitors in the management of moderate to severe hidradenitis suppurativa treatment: a scoping review","volume":"316","author":"Guermazi","year":"2024","journal-title":"Arch Dermatol Res"},{"issue":"10378","key":"10.1016\/j.det.2024.12.016_bib2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.det.2024.12.016_bib3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.det.2024.12.016_bib4","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1111\/jdv.16213","article-title":"Publication trends in hidradenitis suppurativa from 2008 to 2018","volume":"34","author":"Savage","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.det.2024.12.016_bib5","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.det.2024.12.016_bib6","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.12688\/f1000research.17267.1","article-title":"A\u00a0systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa","volume":"7","author":"Frew","year":"2018","journal-title":"F1000Research"},{"issue":"1","key":"10.1016\/j.det.2024.12.016_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00253-007-1142-2","article-title":"Properties, production, and applications of camelid single-domain antibody fragments","volume":"77","author":"Harmsen","year":"2007","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.det.2024.12.016_bib8","article-title":"The role of OX40-OX40L axis in the pathogenesis of atopic dermatitis","author":"Schettini","year":"2024","journal-title":"Dermatitis"},{"issue":"3","key":"10.1016\/j.det.2024.12.016_bib9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1074-7613(01)00191-1","article-title":"OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells","volume":"15","author":"Rogers","year":"2001","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.det.2024.12.016_bib10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/bjd\/ljad240","article-title":"Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial","volume":"189","author":"Weidinger","year":"2023","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.12.016_bib11","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028522","article-title":"Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications","volume":"10","author":"Monin","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"6","key":"10.1016\/j.det.2024.12.016_bib12","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/bjd.14075","article-title":"Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa","volume":"173","author":"Kelly","year":"2015","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.016_bib13","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjd.14214","article-title":"Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa","volume":"174","author":"Lima","year":"2016","journal-title":"Br J Dermatol"},{"issue":"10443","key":"10.1016\/j.det.2024.12.016_bib14","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.det.2024.12.016_bib15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/jdv.13216","article-title":"HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study","volume":"30","author":"Kimball","year":"2016","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2024.12.016_bib16","author":"Brunk"},{"issue":"4","key":"10.1016\/j.det.2024.12.016_bib17","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.immuni.2019.03.012","article-title":"Interleukin-1 and related cytokines in the regulation of inflammation and immunity","volume":"50","author":"Mantovani","year":"2019","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.det.2024.12.016_bib18","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2133.2011.10698.x","article-title":"Adalimumab (antitumour necrosis factor-\u03b1) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex\u00a0vivo study","volume":"166","author":"van der Zee","year":"2012","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.016_bib19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jid.2020.06.019","article-title":"A\u00a0systematic review of promising therapeutic targets in hidradenitis suppurativa: a critical evaluation of mechanistic and clinical relevance","volume":"141","author":"Frew","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.016_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.det.2024.12.016_bib21","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jamadermatol.2013.5377","article-title":"Successful treatment of severe hidradenitis suppurativa with anakinra","volume":"149","author":"Zarchi","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.016_bib22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaad.2013.09.044","article-title":"An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa","volume":"70","author":"Leslie","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.016_bib23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3390\/biom14020175","article-title":"Therapeutic potential of IL-1 antagonism in hidradenitis suppurativa","volume":"14","author":"Calabrese","year":"2024","journal-title":"Biomolecules"},{"issue":"11","key":"10.1016\/j.det.2024.12.016_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/ijd.14596","article-title":"Long-term therapy with anakinra in hidradenitis suppurativa in three patients","volume":"58","author":"Andr\u00e9","year":"2019","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.12.016_bib25","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","article-title":"MABp1 targeting IL-1\u03b1 for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study","volume":"138","author":"Kanni","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"issue":"8","key":"10.1016\/j.det.2024.12.016_bib26","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jid.2019.10.024","article-title":"A\u00a0phase II open-label study of Bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain","volume":"140","author":"Gottlieb","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2024.12.016_bib27","article-title":"Lutikizumab demonstrates positive results in phase 2 trial for hidradenitis suppurativa","author":"Andrus","year":"2024","journal-title":"Dermatol Times"},{"key":"10.1016\/j.det.2024.12.016_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/5584_2017_59","article-title":"The P2X7 receptor","volume":"1051","author":"Sluyter","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"366","key":"10.1016\/j.det.2024.12.016_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8463","article-title":"Nanobodies that block gating of the P2X7 ion channel\u00a0ameliorate inflammation","volume":"8","author":"Danquah","year":"2016","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.det.2024.12.016_bib31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000502026","article-title":"The P2X7 receptor is overexpressed in the lesional skin of subjects affected by hidradenitis suppurativa: a preliminary study","volume":"237","author":"Manfredini","year":"2021","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.det.2024.12.016_bib32","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.3390\/cimb46030161","article-title":"The NLRP3 inflammasome gene is overexpressed in hidradenitis suppurativa lesions: a preliminary study on the role of pyroptosis in disease pathogenesis","volume":"46","author":"Krajewski","year":"2024","journal-title":"Curr Issues Mol Biol"},{"issue":"12","key":"10.1016\/j.det.2024.12.016_bib33","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.bcp.2010.06.020","article-title":"The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling","volume":"80","author":"Flannery","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.det.2024.12.016_bib34","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pharmthera.2017.02.027","article-title":"Targeted protein degradation by PROTACs","volume":"174","author":"Neklesa","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.det.2024.12.016_bib35","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1038\/s41591-023-02635-7","article-title":"IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial","volume":"29","author":"Ackerman","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.det.2024.12.016_bib36","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300155","article-title":"Brepocitinib, simlovisertib, and ropsacitinib in hidradenitis suppurativa","volume":"3","author":"Kimball","year":"2024","journal-title":"NEJM Evid"},{"issue":"3","key":"10.1016\/j.det.2024.12.016_bib37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000529848","article-title":"Tunnels in hidradenitis suppurativa: active inflammatory entities with specific molecular and genetic profiles - a narrative review","volume":"239","author":"Krajewski","year":"2023","journal-title":"Dermatol Basel Switz"},{"issue":"3","key":"10.1016\/j.det.2024.12.016_bib38","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.16019","article-title":"Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop","volume":"178","author":"Hessam","year":"2018","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.det.2024.12.016_bib39","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1111\/jdv.14389","article-title":"Increased expression of the interleukin-36 cytokines in lesions of hidradenitis suppurativa","volume":"31","author":"Thomi","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"14","key":"10.1016\/j.det.2024.12.016_bib40","doi-asserted-by":"crossref","first-page":"13677","DOI":"10.1074\/jbc.M400117200","article-title":"Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs","volume":"279","author":"Towne","year":"2004","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"10.1016\/j.det.2024.12.016_bib41","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jid.2023.11.004","article-title":"Emerging role of the IL-36\/IL-36r Axis in multiple inflammatory skin diseases","volume":"144","author":"Ahmad","year":"2024","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2024.12.016_bib42","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fcell.2019.00317","article-title":"Function and regulation of IL-36 signaling in inflammatory diseases and cancer development","volume":"7","author":"Queen","year":"2019","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"10.1016\/j.det.2024.12.016_bib43","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.4049\/jimmunol.1000313","article-title":"IL-1RL2 and its ligands contribute to the cytokine network in psoriasis","volume":"185","author":"Blumberg","year":"2010","journal-title":"J\u00a0Immunol"},{"issue":"4","key":"10.1016\/j.det.2024.12.016_bib44","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.4049\/jimmunol.1003162","article-title":"IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression","volume":"186","author":"Johnston","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"11","key":"10.1016\/j.det.2024.12.016_bib45","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1172\/JCI63451","article-title":"Psoriasiform dermatitis is driven by IL-36\u2013mediated DC-keratinocyte crosstalk","volume":"122","author":"Tortola","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"10.1016\/j.det.2024.12.016_bib46","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/exd.13228","article-title":"IL-36\u03b3 has proinflammatory effects on human endothelial cells","volume":"26","author":"Bridgewood","year":"2017","journal-title":"Exp Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.016_bib47","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/bjd.20969","article-title":"Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies","volume":"186","author":"Alavi","year":"2022","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.016_bib48","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.det.2024.12.016_bib49","author":"Brunk"},{"issue":"3","key":"10.1016\/j.det.2024.12.016_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2023.07.172","article-title":"43799 efficacy and safety of upadacitinib in moderate-to-severe hidradenitis suppurativa: a phase 2, randomized, placebo-controlled study","volume":"89","author":"Kimball","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.016_bib51","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jaad.2023.10.034","article-title":"Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study","volume":"90","author":"Kirby","year":"2024","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.016_bib81","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jaad.2022.07.047","article-title":"Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: a retrospective cohort study","volume":"87","author":"Kozera","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"19","key":"10.1016\/j.det.2024.12.016_bib53","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139930","article-title":"Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis","volume":"5","author":"Gudjonsson","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.det.2024.12.016_bib54","author":"Brunk"},{"issue":"4","key":"10.1016\/j.det.2024.12.016_bib55","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jaci.2022.10.034","article-title":"Neutrophilic granulocyte-derived B-cell activating factor supports B cells in skin lesions in hidradenitis suppurativa","volume":"151","author":"Sabat","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.det.2024.12.016_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122761","article-title":"Adipose-derived mesenchymal stromal cells in clinical trials: insights from single-cell studies","volume":"351","author":"Kostecka","year":"2024","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.det.2024.12.016_bib57","first-page":"445","article-title":"Role of mesenchymal stromal cells as therapeutic agents: potential mechanisms of action and implications in their clinical use","volume":"9","author":"Jimenez-Puerta","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"9","key":"10.1016\/j.det.2024.12.016_bib58","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/ijd.14036","article-title":"Ertapenem - a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa","volume":"57","author":"Braunberger","year":"2018","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.016_bib59","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jac\/dkv361","article-title":"Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients","volume":"71","author":"Join-Lambert","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.det.2024.12.016_bib60","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jid.2019.08.445","article-title":"Skin microbiota perturbations are distinct and disease severity-dependent in hidradenitis suppurativa","volume":"140","author":"Naik","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.016_bib61","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3390\/biomedicines10051087","article-title":"Aryl hydrocarbon receptors: evidence of therapeutic targets in chronic inflammatory skin diseases","volume":"10","author":"Kim","year":"2022","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.det.2024.12.016_bib62","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.3390\/cells10113176","article-title":"Role of AHR ligands in skin homeostasis and cutaneous inflammation","volume":"10","author":"Fern\u00e1ndez-Gallego","year":"2021","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.det.2024.12.016_bib63","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.jaci.2018.11.036","article-title":"A\u00a0tryptophan metabolite of the skin microbiota attenuates inflammation in patients with atopic dermatitis through the aryl hydrocarbon receptor","volume":"143","author":"Yu","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"24","key":"10.1016\/j.det.2024.12.016_bib64","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","article-title":"Phase 3 trials of tapinarof cream for plaque psoriasis","volume":"385","author":"Lebwohl","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.det.2024.12.016_bib65","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jaad.2020.05.135","article-title":"Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis","volume":"84","author":"Paller","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2024.12.016_bib66","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s13555-023-00956-6","article-title":"Emerging treatments and the clinical trial landscape for hidradenitis suppurativa Part I: topical and systemic medical therapies","volume":"13","author":"Fragoso","year":"2023","journal-title":"Dermatol Ther"},{"issue":"7454","key":"10.1016\/j.det.2024.12.016_bib67","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature12175","article-title":"Neutrophil swarms require LTB4 and integrins at sites of cell death in\u00a0vivo","volume":"498","author":"L\u00e4mmermann","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.det.2024.12.016_bib68","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cytogfr.2023.11.002","article-title":"Harnessing the potential of CD40 agonism in cancer therapy","volume":"75","author":"Zhou","year":"2024","journal-title":"Cytokine Growth Factor Rev"},{"issue":"12","key":"10.1016\/j.det.2024.12.016_bib69","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1111\/ajt.14872","article-title":"Characterization of the in\u00a0vitro and in\u00a0vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody","volume":"18","author":"Ristov","year":"2018","journal-title":"Am J Transplant"},{"issue":"27","key":"10.1016\/j.det.2024.12.016_bib70","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000187","article-title":"Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases","volume":"93","author":"Marzano","year":"2014","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.det.2024.12.016_bib71","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jocn.2023.11.013","article-title":"Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: a phase 2 randomized study","volume":"119","author":"GomezMancilla","year":"2024","journal-title":"J\u00a0Clin Neurosci"},{"issue":"2","key":"10.1016\/j.det.2024.12.016_bib72","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/ajt.15661","article-title":"First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody","volume":"20","author":"Espi\u00e9","year":"2020","journal-title":"Am J Transpl"},{"issue":"3","key":"10.1016\/j.det.2024.12.016_bib73","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz013","article-title":"A\u00a0novel anti-CD40 monoclonal antibody, iscalimab, for control of Graves hyperthyroidism-A proof-of-concept trial","volume":"105","author":"Kahaly","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.det.2024.12.016_bib74","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren\u2019s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.det.2024.12.016_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115175","article-title":"Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers","volume":"250","author":"Xie","year":"2023","journal-title":"Eur J Med Chem"},{"issue":"5","key":"10.1016\/j.det.2024.12.016_bib76","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.yexcr.2011.01.005","article-title":"Chemokines in health and disease","volume":"317","author":"Raman","year":"2011","journal-title":"Exp Cell Res"},{"issue":"2","key":"10.1016\/j.det.2024.12.016_bib77","first-page":"95","article-title":"Chemokines and chemokine receptors: their manifold roles in homeostasis and disease","volume":"1","author":"Le","year":"2004","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"10.1016\/j.det.2024.12.016_bib78","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1365-2133.2011.10765.x","article-title":"Immunohistological pointers to a possible role for excessive cathelicidin (LL-37) expression by apocrine sweat glands in the pathogenesis of hidradenitis suppurativa\/acne inversa","volume":"166","author":"Emelianov","year":"2012","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.016_bib79","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1831880","article-title":"Discovery and characterization of a neutralizing pan-ELR+CXC chemokine monoclonal antibody","volume":"12","author":"Boyles","year":"2020","journal-title":"mAbs"},{"key":"10.1016\/j.det.2024.12.016_bib80","author":"Duerr"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524001165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524001165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T17:31:06Z","timestamp":1751391066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863524001165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0733863524001165"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.12.016","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Future Directions and Pipeline Therapies for Hidradenitis Suppurativa","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}